title: Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.
abstract: The efficacy of beta-lactam antibiotics and amikacin alone and in various combinations against Pseudomonas aeruginosa was studied in a rabbit model simulating a closed-space infection in a locally neutropenic site. Six strains of P. aeruginosa were studied in semipermeable chambers placed subcutaneously in rabbits. Therapy was begun 4 h after inoculation of 5 X 10(4) CFU of bacteria per ml of pooled rabbit serum into the chambers. Antibiotics were administered intramuscularly every 6 h for 16 doses. Quantitative bacteriology was measured at the start of therapy and at 20, 44, and 92 h thereafter. Antibiotic concentrations were measured in blood and chamber fluid. Results were compared with in vitro tests of susceptibility and synergy. No single-agent therapy eradicated any of the six test organisms. Azlocillin (100 mg/kg per dose) plus amikacin (20 mg/kg per dose) eliminated five of six organisms by 92 h, and ceftizoxime (100 mg/kg per dose) plus amikacin (20 mg/kg per dose) eliminated three of six test strains. Azlocillin plus ceftizoxime (each 100 mg/kg per dose) failed to eliminate any of the six strains. To eliminate P. aeruginosa in this model, two drugs were required, with one being an aminoglycoside. In vitro susceptibility tests of synergy were predictive of successful therapy whenever the antibiotic concentrations (free and total) at the infection site exceeded the MBC for both the aminoglycoside alone and the beta-lactam when tested in combination with amikacin.
mesh_terms: D000380:Agranulocytosis / Q000382:microbiology*; D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001390:Azlocillin; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D002440:Cefoxitin / Q000627:therapeutic use; D015296:Ceftizoxime; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D006863:Hydrogen-Ion Concentration; D007612:Kanamycin / Q000031:analogs & derivatives*; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000382:microbiology*; D010406:Penicillins / Q000627:therapeutic use; D011485:Protein Binding / Q000187:drug effects; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011817:Rabbits
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D010406:Penicillins; D007612:Kanamycin; D002440:Cefoxitin; D000583:Amikacin; D015296:Ceftizoxime; D001390:Azlocillin; D002439:Cefotaxime